Monoclonal Antibodies in Veterinary Health Market Report 2025

This monoclonal antibodies in veterinary health market report delivers an in-depth analysis of the market’s key characteristics, including size, growth potential, and segmentation. It provides a detailed breakdown of the market across major regions and leading countries, highlighting historical data and future growth projections. The report also examines the competitive landscape, market share insights, emerging trends, and strategic developments shaping the market.

The monoclonal antibodies in veterinary health market size has grown rapidly in recent years. It will grow from $0.8 billion in 2024 to $0.92 billion in 2025 at a compound annual growth rate (CAGR) of 15.2%. The growth in the historic period can be attributed to an increase in pet ownership worldwide, the prevalence of chronic diseases in animals, an increase in the number of pet adoption rates, and increased health concerns among pet owners.

The monoclonal antibodies in veterinary health market size is expected to see rapid growth in the next few years. It will grow to $1.61 billion in 2029 at a compound annual growth rate (CAGR) of 15%. The growth in the forecast period can be attributed to the increasing pet population, rising pet expenditure, growing prevalence of canine atopic dermatitis, increasing demand for advanced veterinary healthcare, and rising importance of animal health. Major trends in the forecast period include advancements in biotechnology and research, genetic engineering advancements, innovative treatments, advancements in antibody-based therapeutics, and technological advancements in antibody engineering.

The increasing incidence of animal diseases is anticipated to drive the growth of the monoclonal antibodies in veterinary health market. These rising disease rates are attributed to intensified farming practices, which heighten the risk of infectious diseases, and climate change, which broadens the range of disease vectors such as ticks and mosquitoes. Monoclonal antibodies are highly effective for treating animal diseases because they specifically target pathogens or proteins involved in disease processes, offering precise and effective treatments. For example, a June 2024 report from GOV.UK noted that from April 2023 to March 2024, the number of animals slaughtered due to tuberculosis (TB) incidents increased by 5% in England to 21,298, and by 17% in Wales to 11,197. This rise in animal disease cases is fueling the growth of the monoclonal antibodies market in veterinary health.

Leading companies in the monoclonal antibodies in veterinary health market are developing advanced therapeutic solutions, such as anti-NGF monoclonal antibody treatments, to address conditions such as chronic pain and inflammation in animals. Anti-NGF monoclonal antibody treatment targets and inhibits nerve growth factor (NGF), reducing pain and inflammation in animals with chronic pain conditions. For instance, in May 2023, Zoetis, a US-based animal health company, received FDA approval for Librela (bedinvetmab injection), the first monoclonal antibody treatment for managing pain associated with osteoarthritis (OA) in dogs. Librela is administered as a monthly injection and works by targeting NGF to block pain signals from reaching the brain, thereby alleviating pain. Additionally, Zoetis launched Apoquel Chewable, the first chewable medication for managing allergic itch and inflammation in dogs aged one year or older. Librela represents a significant advancement in veterinary pain management, offering a new approach to treating chronic pain in dogs.

In January 2024, Ceva Santé Animale, a France-based provider of animal health products and services, acquired Scout Bio Inc. for an undisclosed amount. This acquisition is intended to boost Ceva Santé’s global biotechnology initiatives in animal health by leveraging Scout Bio's expertise in advanced therapies, such as gene therapy and monoclonal antibodies. Scout Bio Inc., a US-based biotechnology firm, is known for developing a pipeline of monoclonal antibody therapies aimed at treating chronic conditions in pets.

Major companies operating in the monoclonal antibodies in veterinary health market are Sanofi S.A., Bristol-Myers Squibb Company, GlaxoSmithKline plc (GSK), Amgen Inc., Boehringer Ingelheim International GmbH, Regeneron Pharmaceuticals Inc., Zoetis Inc., MSD Animal Health, Elanco Animal Health Incorporated, Bio-Rad Laboratories Inc., Eli Lilly and Company, GenScript Biotech Corporation, Abcam plc, Heska Corporation, Neogen Corporation, iNova Pharmaceuticals, Ceva Santé Animale S.A., Biogénesis Bagó S.A., TransGen Biotech Co. Ltd., AbCellera Biologics Inc., Areteia Therapeutics Inc., Esco Aster Pte Ltd, PetMedix Ltd., Vaxine Pty Ltd.

North America was the largest region in the monoclonal antibodies in veterinary health market in 2024. The regions covered in the monoclonal antibodies in veterinary health market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the monoclonal antibodies in veterinary health market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Monoclonal antibodies in veterinary health are engineered proteins designed to target and neutralize specific pathogens or toxins in animals, assisting in the diagnosis and treatment of various diseases. They are produced by cloning a single type of immune cell to generate identical antibodies that specifically bind to their target.

Monoclonal antibodies in veterinary health are primarily used for dogs, although they can also be used for other animals. Monoclonal antibodies are applied in fields such as dermatology and pain management, with end users including veterinary hospitals and other related facilities.

The monoclonal antibodies in veterinary health market research report is one of a series of new reports that provides monoclonal antibodies in veterinary health market statistics, including monoclonal antibodies in veterinary health industry global market size, regional shares, competitors with a monoclonal antibodies in veterinary health market share, detailed monoclonal antibodies in veterinary health market segments, market trends and opportunities, and any further data you may need to thrive in the monoclonal antibodies in veterinary health industry. This monoclonal antibodies in veterinary health market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The monoclonal antibodies in veterinary health market consist of sales of diagnostic kits, therapeutic drugs, research reagents, monoclonal antibody drugs, and therapeutic formulations. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 3-5 business days.